🇺🇸 Esperion Therapeutics Inc
ESPRFundamentals
Gross Margin
-
Op. Margin
16.4%
Net Margin
-15.6%
ROIC
-
Rev Growth
185.7%
Valuation
Price
-
Day
-
52-Week Range
1.21 - 4.17
Market Cap
819M USD
Fwd P/E
12.3x
EV/EBITDA
15.9x
Div Yield
-
Annual income statement #
Esperion Therapeutics Inc annual revenue, operating income and net income in USD, 2000 to 2024. Revenue was 332.3m in 2024.
| Year | Revenue (USD) | Operating income | Net income | Net margin |
|---|---|---|---|---|
| 2024 | 332.3m | 54.4m | -51.7m | -15.6% |
| 2023 | 116.3m | -155.6m | -209.2m | |
| 2022 | 75.5m | -179.5m | -233.7m | |
| 2021 | 78.5m | -226.7m | -269.1m | |
| 2020 | 227.6m | -121.4m | -143.6m | -63.1% |
| 2019 | 148.4m | -93.1m | -97.2m | -65.5% |
| 2018 | 184.5m | -204.6m | -201.8m | |
| 2013 | 4.98bn | -22.8m | -26.1m | -0.5% |
| 2000 | 2,000 | -27.6m | -27.6m |
Financial Data #
Segment Breakdown #
Events #
| Date | Type | Details | Price | Amount |
|---|